VEGFA and neoplasm: The rational selection of the first-line individualized therapy, between anti-EGFR therapy and anti-VEGF therapy, is only possible if the patient benefits of tumor KRAS mutation testing, whereas without this determination, the therapeutic choice would be done by default.